Peripheral CB1 Antagonists via Blood-Brain Barrier Restriction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current obesity treatments, such as sibutramine and orlistat, achieve only modest weight loss and are associated with undesirable side effects, while CB1 receptor antagonists like rimonabant have CNS-related adverse effects due to non-selective targeting of CB1 receptors.
Innovation Solution
Development of novel pyrazole-based CB1 receptor antagonists/inverse agonists that preferentially target peripheral tissues, reducing CNS exposure and side effects by limiting penetration across the blood-brain barrier or participating in active transport systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If CB1 receptor antagonists like rimonabant are used to treat obesity, then weight loss is achieved, but CNS-related adverse effects occur due to non-selective targeting of CB1 receptors
Solution Approach 1:
The patent applies local quality by designing compounds with differential distribution properties - the compounds concentrate in peripheral tissues (adipose tissue, liver, muscle) while maintaining low concentrations in the CNS. This is achieved through specific molecular structure modifications that affect blood-brain barrier penetration, allowing the same compound to have high activity where needed (peripheral CB1 receptors) and low activity where harmful (CNS CB1 receptors).
Solution Approach 2:
The patent uses the blood-brain barrier as an intermediary mechanism to achieve selective drug distribution. By designing compounds with specific physicochemical properties (molecular weight, lipophilicity, charge), the blood-brain barrier acts as a selective filter that allows therapeutic compounds to reach peripheral tissues while blocking their entry into the CNS, thereby mediating selective drug action without direct targeting of CNS receptors.
2Productivity
If current obesity treatments such as sibutramine and orlistat are used, then modest weight loss is achieved, but undesirable side effects and limited effectiveness occur
Solution Approach 1:
The patent extracts the therapeutic benefit of CB1 receptor antagonism from the harmful CNS effects by selectively targeting peripheral CB1 receptors. This is achieved by removing or reducing the compound's ability to cross into the CNS while preserving its ability to bind and antagonize CB1 receptors in peripheral tissues, thereby extracting the weight loss mechanism while leaving behind the CNS-related side effects.
Solution Approach 2:
The patent applies parameter changes by modifying key physicochemical parameters of the CB1 antagonist compounds - specifically molecular weight, lipophilicity (logP), and charge state - to optimize their distribution profile. These parameter changes enable the compounds to maintain adequate plasma concentrations for peripheral tissue penetration while achieving sufficiently low brain concentrations to minimize CNS side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds achieve significant weight loss and improve cardiometabolic risk factors with reduced CNS side effects, offering a safer and more effective treatment for obesity and related disorders.
Implementation Method 1
CB1 receptor antagonists/inverse agonists useful for treating obesity
Implementation Method 2
limiting penetration across the blood-brain barrier
Implementation Method 3
or participating in active transport systems
Data Source
AI summary
The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.